Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation and systemic inflammation, with the cardiovascular (CV) system representing a major yet frequently under-recognized target. Cardiac involvement spans from subclinical myocardial inflammation to overt pericardial disease, myocarditis, valvular abnormalities, coronary microvascular dysfunction, and accelerated atherosclerosis. Given that CV disease remains a leading cause of morbidity and mortality in SLE, early detection of silent cardiac injury is crucial. Aim: This review aims to provide a comprehensive and clinically oriented overview of CV involvement in SLE, focusing on the role of multimodal cardiac imaging in the detection, characterization, and risk stratification of cardiac abnormalities, as well as its potential implications for clinical management and preventive strategies. Methods: This narrative review is based on a structured, non-systematic search of PubMed (2013–2026), combining the term “systemic lupus erythematosus” with imaging-related keywords including “transthoracic echocardiography,” “cardiac magnetic resonance,” and “cardiac computed tomography.” English-language studies in adult populations were screened and selected according to clinical relevance, methodological robustness, and contribution to understanding SLE-related cardiac involvement. Discussion: Multimodal cardiac imaging plays a central role in the evaluation of SLE-related cardiac disease. Transthoracic echocardiography (TTE) represents the first-line modality for the assessment of ventricular function, pericardial disease, and valvular abnormalities, while deformation imaging enables the detection of subtle myocardial dysfunction. Cardiac magnetic resonance (CMR) provides comprehensive tissue characterization, allowing differentiation between active inflammation and chronic fibrosis. Cardiac computed tomography (cCT) identifies subclinical coronary atherosclerosis and high-risk plaque features, whereas nuclear imaging techniques offer insight into inflammatory activity and microvascular dysfunction. Conclusions: An integrated, imaging-based approach enables early diagnosis, refined CV risk stratification, longitudinal monitoring, and personalized therapeutic strategies. Multimodal imaging thus represents a key pillar of precision medicine in lupus-associated CV disease.

Background: Serum uric acid (UA) is increasingly recognized as a cardiovascular (CV) risk factor, with evidence suggesting that CV risk may occur at levels below conventional hyperuricemia thresholds. However, real-world comparative data on the effects of dietary interventions on UA are limited. Objective: The primary objective of this study was to compare the effects of a very low-calorie ketogenic diet (VLCKD), intermittent fasting (IF), and standard dietary advice (free diet, FD) on UA levels and UA-defined CV risk in hypertensive postmenopausal women. Methods: In this prospective, single-center, real-world clinical study, 43 women with essential hypertension and obesity underwent dietary interventions. UA levels were assessed at baseline and after 6 months. Hyperuricemia was defined using both the conventional threshold (≥6.0 mg/dL) and the CV risk-oriented Uric Acid Right for Heart Health (URRAH) cut-off (≥4.7 mg/dL). Analyses included paired tests and ANCOVA adjusted for baseline UA. Results: At baseline, over half of participants exceeded the URRAH threshold. Only VLCKD significantly reduced UA levels (−1.23 mg/dL; p < 0.001), remaining independently associated after adjustment (β = −0.95 mg/dL; p = 0.007). URRAH-defined CV risk decreased significantly only in the VLCKD group (55.6% to 22.2%), with one-third transitioning to lower risk. Conclusions: VLCKD significantly reduced UA levels and UA-defined CV risk, supporting its role as a potentially effective lifestyle intervention in this population.